Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
캐나다 앨버타주 캘거리, June 03, 2023 (GLOBE NEWSWIRE) -- 메신저 리보핵산(mRNA) 백신, 치료제 개발사인 Providence Therapeutics Holdings Inc.는 University Health Network (UHN)와 mRNA 신약 후보물질 발굴에 대한 파트너십을 체결했다고 발표했다. UHN은...
-
CALGARY, Alberta, June 02, 2023 (GLOBE NEWSWIRE) -- Providence Therapeutics Holdings Inc. ("Providence"), a biopharmaceutical company developing messenger RNA (mRNA) vaccines and therapeutics, today...
-
CALGARY, Alberta, Feb. 01, 2023 (GLOBE NEWSWIRE) -- Providence Therapeutics Holdings Inc. ("Providence"), a biopharmaceutical company developing messenger RNA (mRNA) vaccines and therapeutics, today...
-
Novel rabies vaccine candidate developed with Providence’s mRNA platform further validates the technology Providence continues to expand its mRNA platform to target infectious diseases and oncology ...
-
Presentation highlights data from PRO-CL-002 Phase 2 study of Providence’s mRNA COVID-19 vaccine candidate, PTX-COVID19-BPTX-COVID19-B was well tolerated with no safety signals; non-inferior to...
-
CALGARY, Alberta, Nov. 02, 2022 (GLOBE NEWSWIRE) -- Providence Therapeutics Holdings Inc. ("Providence"), a biopharmaceutical company developing messenger RNA (mRNA) vaccines and therapeutics,...
-
PTX-COVID19-B was well tolerated with no safety signalsNon-inferior neutralizing antibody titer levels versus comparator vaccine, Comirnaty®Providence will initiate a Phase 3 trial of PTX-COVID19-B in...